DarioHealth to Present at the OurCrowd Global Investor Summit

DarioHealth to discuss its successful direct-to-consumer strategy and results

Team of DarioHealth experts attending, will showcase the Dario™ Blood Glucose Monitoring System

Feb 8, 2017

BOSTON, Feb. 8, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, today announced that its Chairman and Chief Executive Officer, Erez Raphael, will be presenting at the annual OurCrowd's Global Investor Summit in Jerusalem, Israel on February 16, 2017.

395077LOGO

In addition, DarioHealth will have a booth at the summit and members of the team will be on hand showcasing the Dario™ Blood Glucose Monitoring System.

Erez Raphael is slated to present about DarioHealth's direct-to-consumer strategy and results. He is also set to take part in some panel discussions and share the latest insights on how DarioHealth is successfully combining traditional tools with digital technology.

Last month, DarioHealth secured the first investment by OurCrowd Qure, Israel's first fund focused exclusively on digital health. DarioHealth continues expanding its global reach, as it has already gained considerable traction with a user-centric approach for diabetes treatment in the U.S., Canada, Australia and other countries. This year, the company plans to expand into the German market.

The OurCrowd Global Investor Summit will be the world's largest equity crowdfunding event and the biggest investor event in Israel, with over 5,000 attendees from over 80 countries expected to attend. The summit attracts some 200 multinational companies, venture and corporate partners, entrepreneurs, dozens of global delegations, industry leaders and members of the press.

For more information about the OurCrowd Global Investor Summit, go to: http://summit.ourcrowd.com/, the content of which is not incorporated by reference herein.

About DarioHealth Corp.

DarioHealth is a leader in digital health self-management solutions. DarioHealth delivers the ability to combine and analyze consumer health data to personalize treatment and advance medical knowledge. Dario's™ smart diabetes management solution is a platform for diabetes management that combines the Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter, native smart phone app, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.  Having recently launched in the largest market in the world for glucose monitoring, U.S. sales are expected to have a significant impact on revenues and gross margins. With marketing clearance in Europe and the U.S., the Dario iOS mobile app recently launched with reimbursement in the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium.  For more information, visit http://mydario.investorroom.com/

About the 2017 OurCrowd Global Investor Summit

The OurCrowd Global Investor Summit is the largest equity crowdfunding event in the world, and the biggest investor event in the Startup Nation.  Now in its third year, the Summit has hosted thousands of investors, venture and corporate partners, entrepreneurs, global delegations, industry leaders and members of the press. Attendees hailing from more than 80 countries gather in Jerusalem, the capital of the Startup Nation, to celebrate the global community's collective drive for innovation. Each year, attendees come from all over the world to hear from expert industry speakers and participate in interactive programming featuring cutting-edge technologies and the future of crowd investing.  They also have the opportunity to support portfolio companies through significant fundraising and making strategic business connections to help grow their businesses.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements.  For example, when the Company discusses its plans to expand into the German market, describes its growth potential, and says that U.S. sales are expected to have a significant impact on the Company's revenues and gross margins, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director  
shmuel@mydario.com   
+1-800-896-9062

 

DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas   
DRIO@HaydenIR.com  
646-415-8972 / 646-536-7331

 

OurCrowd Media Contact:
Leah Stern
OurCrowd Communications Director
leah@ourcrowd.com   
+44-747-0196-826  
+972-54-341-4861

 

SOURCE DarioHealth Corp.


print email rss